NUCALA Rx

Select the drug indication to add to your list

NUCALA

Asthma/COPD
Only 4 drugs may be compared at once

Generic Name and Formulations:

Mepolizumab 100mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free.

Company:

GlaxoSmithKline

Select therapeutic use:

Indications for NUCALA:

As add-on maintenance treatment of severe asthma in patients ≥12yrs old, and with an eosinophilic phenotype.

Limitations Of use:

Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.

Adult:

Give by SC inj into upper arm, thigh, or abdomen. 100mg once every 4 weeks.

Children:

Not established.

Warnings/Precautions:

Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Opportunistic infections (eg, herpes zoster); consider varicella vaccination if appropriate prior to starting therapy. Treat pre-existing helminth infections before initiating therapy; discontinue Nucala if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Nucala initiation. Reduction may unmask previously suppressed allergic conditions. Elderly. Pregnancy (monitor closely). Nursing mothers.

Pharmacological Class:

Interleukin-5 antagonist.

Adverse Reactions:

Headache, inj site reactions, back pain, fatigue; infections, hypersensitivity reactions; possible antibody formation.

Generic Availability:

NO

How Supplied:

Single-dose vial—1

NUCALA 100mg vials (Qty:1)

appx. price $2919.00